JP2026504636A5 - - Google Patents

Info

Publication number
JP2026504636A5
JP2026504636A5 JP2025528632A JP2025528632A JP2026504636A5 JP 2026504636 A5 JP2026504636 A5 JP 2026504636A5 JP 2025528632 A JP2025528632 A JP 2025528632A JP 2025528632 A JP2025528632 A JP 2025528632A JP 2026504636 A5 JP2026504636 A5 JP 2026504636A5
Authority
JP
Japan
Prior art keywords
antibody
cancer
salt
drug conjugate
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025528632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2026504636A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/080162 external-priority patent/WO2024108053A1/en
Publication of JP2026504636A publication Critical patent/JP2026504636A/ja
Publication of JP2026504636A5 publication Critical patent/JP2026504636A5/ja
Pending legal-status Critical Current

Links

JP2025528632A 2022-11-17 2023-11-16 Ceacam5抗体-薬物コンジュゲート及びその使用方法 Pending JP2026504636A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263384214P 2022-11-17 2022-11-17
US63/384,214 2022-11-17
EP22306780 2022-12-02
EP22306780.2 2022-12-02
US202363596943P 2023-11-07 2023-11-07
US63/596,943 2023-11-07
PCT/US2023/080162 WO2024108053A1 (en) 2022-11-17 2023-11-16 Ceacam5 antibody-drug conjugates and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2026504636A JP2026504636A (ja) 2026-02-06
JP2026504636A5 true JP2026504636A5 (cg-RX-API-DMAC7.html) 2026-05-12

Family

ID=89308487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025528632A Pending JP2026504636A (ja) 2022-11-17 2023-11-16 Ceacam5抗体-薬物コンジュゲート及びその使用方法

Country Status (11)

Country Link
US (2) US20240226313A1 (cg-RX-API-DMAC7.html)
EP (1) EP4619045A1 (cg-RX-API-DMAC7.html)
JP (1) JP2026504636A (cg-RX-API-DMAC7.html)
KR (1) KR20250106304A (cg-RX-API-DMAC7.html)
CN (1) CN120417937A (cg-RX-API-DMAC7.html)
AU (1) AU2023379743A1 (cg-RX-API-DMAC7.html)
CO (1) CO2025008047A2 (cg-RX-API-DMAC7.html)
IL (1) IL320894A (cg-RX-API-DMAC7.html)
MX (1) MX2025005811A (cg-RX-API-DMAC7.html)
TW (1) TW202435917A (cg-RX-API-DMAC7.html)
WO (1) WO2024108053A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3199552T (pt) * 2012-11-20 2020-03-25 Sanofi Sa Anticorpos anti-ceacam5 e suas utilizações
TWI920652B (zh) 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物
JP7849358B2 (ja) 2020-11-10 2026-04-21 サノフイ Ceacam5抗体-薬物コンジュゲート製剤
WO2026019161A1 (ko) * 2024-07-19 2026-01-22 주식회사 다안바이오테라퓨틱스 신규한 항-ceacam5 항체 및 그의 치료제로서의 용도
WO2026149515A1 (zh) * 2025-01-11 2026-07-16 泰诚思(上海)生物医药有限公司 新型喜树碱衍生物、其制备方法及用途、抗体药物偶联物及其应用
CN121613114A (zh) * 2025-12-22 2026-03-06 北京迈格松生物科技有限公司 一种基于中性粒细胞迁移体及其标志物检测的弥散性血管内凝血早期诊断方法

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2724675A1 (de) 1977-06-01 1978-12-14 Bayer Ag Tetrahydrofuran-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
EP0582595A1 (en) 1991-04-26 1994-02-16 Surface Active Limited Novel antibodies, and methods for their use
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP2763020B2 (ja) 1995-04-27 1998-06-11 日本電気株式会社 半導体パッケージ及び半導体装置
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
EP1731174A3 (en) 1996-08-02 2007-01-17 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
MY128897A (en) 1999-02-05 2007-02-28 Samsung Electronics Co Ltd Image texture retrieving method and apparatus thereof
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
ITMI20041427A1 (it) 2004-07-15 2004-10-15 Univ Degli Studi Milano Sintesi di molecole organometalliche utilizzabili come marcatori di sostanze organiche
AU2005290250A1 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CA2676529C (en) 2007-01-24 2014-03-25 Kyowa Kirin Co., Ltd. Genetically recombinant antibody composition having enhanced effector activity
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CN104822656B (zh) 2012-05-15 2018-05-01 西雅图基因公司 自稳定接头偶联物
PT3057585T (pt) 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
EP3433278A4 (en) 2016-03-25 2019-11-06 Seattle Genetics, Inc. METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
TWI920652B (zh) * 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物
EP4138925A1 (en) * 2020-04-24 2023-03-01 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil
US20250122282A2 (en) * 2020-09-04 2025-04-17 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof

Similar Documents

Publication Publication Date Title
JP2010539981A5 (cg-RX-API-DMAC7.html)
ES2941768T3 (es) Compuestos de 2H-pirazolo[4,3-d]pirimidina como agonistas del receptor 7 tipo toll (TLR7) y métodos y usos para los mismos
JP2023525120A5 (cg-RX-API-DMAC7.html)
AU2019320336B2 (en) Combination of antibody-drug conjugate and tubulin inhibitor
ES2905842T3 (es) Derivados de 6-amino-7,9-dihidro-8h-purin-8-ona como agonistas del receptor tipo Toll 7 (TLR7) como inmunoestimulantes
JP2022095908A5 (cg-RX-API-DMAC7.html)
JP2023539715A5 (cg-RX-API-DMAC7.html)
JP2017095457A5 (cg-RX-API-DMAC7.html)
JP2023542066A5 (cg-RX-API-DMAC7.html)
JP2004529963A5 (cg-RX-API-DMAC7.html)
JPWO2021177438A5 (cg-RX-API-DMAC7.html)
JP2018537975A5 (cg-RX-API-DMAC7.html)
HRP20231609T1 (hr) Konjugati lijeka koji sadrže antitijela protiv klaudina 18.2
JP2019532056A5 (cg-RX-API-DMAC7.html)
JP2023527962A5 (cg-RX-API-DMAC7.html)
JP2023545096A5 (cg-RX-API-DMAC7.html)
EA027925B1 (ru) Ендиины, их конъюгаты и способы их получения и применения
JPWO2019230645A5 (cg-RX-API-DMAC7.html)
JP2020533269A (ja) 抗体−薬物複合体およびその使用
JP2025506768A5 (cg-RX-API-DMAC7.html)
JPWO2020027100A5 (cg-RX-API-DMAC7.html)
JP2020531430A (ja) 抗体を標的とする抗ctla4プロボディ療法
JP2023542065A5 (cg-RX-API-DMAC7.html)
JP2008528671A5 (cg-RX-API-DMAC7.html)
JP2023514167A5 (cg-RX-API-DMAC7.html)